|
|
||||||||

*
Department of Gynecologic Oncology, M. D. Anderson Cancer Center, Houston, TX 77030; and
Department of Microbiology and Immunology, Temple University, Philadelphia, PA 19140
A newly described subset of monocytes has been identified in
peritoneal exudate cells (PEC) from the malignant ascites from patients
with ovarian cancer. These cells were characterized by the production
of IL-10 and TGF-ß2, but not IL-12, IL-1
, or TNF-
, and they
expressed CD14, CD16, and CD54, but not HLA-DR, CD80, CD86, CD11a,
CD11b, or CD25 cell surface Ags. Since this subset of monocytes could
affect the modulation of tumor immune responses in vivo, studies were
undertaken to determine their effect on the activation and
proliferation of autologous T cells from the peritoneal cavity of
patients with ovarian carcinoma. Expression of cytokine-specific
transcripts in T cells was determined by RT-PCR. Transcripts for the
following cytokines were detected in patient specimens that also
contained the IL-10-producing monocytes IL-2 (12 of 17 specimens),
GM-CSF (9 of 17 specimens), IFN-
(6 of 17 specimens), and TNF-
(4
of 17 specimens). Cytokine production by T cells was determined by
intracellular flow cytometry and by ELISA. IL-2 and IFN-
proteins,
unlike their transcripts, were detected only in specimens that lacked
IL-10-producing monocytes. IL-10-producing monocytes cocultured with
autologous T cells inhibited the proliferation of the T cells in
response to PHA. However, T cells cocultured with PEC from which the
IL-10-producing monocytes had been removed did not inhibit T cell
proliferation. Moreover, the inhibition of T cell proliferation by
IL-10-producing monocytes could be reversed by adding neutralizing Abs
to both IL-10R and TGF-ß2. These results suggest that this subset of
monocytes may modulate immune responses by inhibiting T cell
proliferation and cytokine protein production.
This article has been cited by other articles:
![]() |
Y.-C. Chang, T.-C. Chen, C.-T. Lee, C.-Y. Yang, H.-W. Wang, C.-C. Wang, and S.-L. Hsieh Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3 Blood, May 15, 2008; 111(10): 5054 - 5063. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Miselis, Z. J. Wu, N. Van Rooijen, and A. B. Kane Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma Mol. Cancer Ther., April 1, 2008; 7(4): 788 - 799. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Filipazzi, R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani, and L. Rivoltini Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor-Based Antitumor Vaccine J. Clin. Oncol., June 20, 2007; 25(18): 2546 - 2553. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. O. Gordon and R. S. Freedman Defective Antitumor Function of Monocyte-Derived Macrophages from Epithelial Ovarian Cancer Patients Clin. Cancer Res., March 1, 2006; 12(5): 1515 - 1524. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Goodell, L. G. Salazar, N. Urban, C. W. Drescher, H. Gray, R. E. Swensen, M. W. McIntosh, and M. L. Disis Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer J. Clin. Oncol., February 10, 2006; 24(5): 762 - 768. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mocellin, F. M. Marincola, and H. A. Young Interleukin-10 and the immune response against cancer: a counterpoint J. Leukoc. Biol., November 1, 2005; 78(5): 1043 - 1051. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Birdsall, W. J. Porter, J. Trial, and R. D. Rossen Monocytes Stimulated by 110-kDa Fibronectin Fragments Suppress Proliferation of Anti-CD3-Activated T Cells J. Immunol., September 1, 2005; 175(5): 3347 - 3353. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Schutyser, A. Richmond, and J. Van Damme Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes J. Leukoc. Biol., July 1, 2005; 78(1): 14 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Beckebaum, X. Zhang, X. Chen, Z. Yu, A. Frilling, G. Dworacki, H. Grosse-Wilde, C. E. Broelsch, G. Gerken, and V. R. Cicinnati Increased Levels of Interleukin-10 in Serum from Patients with Hepatocellular Carcinoma Correlate with Profound Numerical Deficiencies and Immature Phenotype of Circulating Dendritic Cell Subsets Clin. Cancer Res., November 1, 2004; 10(21): 7260 - 7269. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Oleszak, J. R. Chang, H. Friedman, C. D. Katsetos, and C. D. Platsoucas Theiler's Virus Infection: a Model for Multiple Sclerosis Clin. Microbiol. Rev., January 1, 2004; 17(1): 174 - 207. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Freedman, S. Vadhan-Raj, C. Butts, C. Savary, B. Melichar, C. Verschraegen, J. J. Kavanagh, M. E. Hicks, L. B. Levy, J. K. Folloder, et al. Pilot Study of Flt3 Ligand Comparing Intraperitoneal with Subcutaneous Routes on Hematologic and Immunologic Responses in Patients with Peritoneal Carcinomatosis and Mesotheliomas Clin. Cancer Res., November 1, 2003; 9(14): 5228 - 5237. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Lutgendorf, S. Cole, E. Costanzo, S. Bradley, J. Coffin, S. Jabbari, K. Rainwater, J. M. Ritchie, M. Yang, and A. K. Sood Stress-Related Mediators Stimulate Vascular Endothelial Growth Factor Secretion by Two Ovarian Cancer Cell Lines Clin. Cancer Res., October 1, 2003; 9(12): 4514 - 4521. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Yang and E. C. Lattime Tumor-induced Interleukin 10 Suppresses the Ability of Splenic Dendritic Cells to Stimulate CD4 and CD8 T-Cell Responses Cancer Res., May 1, 2003; 63(9): 2150 - 2157. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, et al. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer N. Engl. J. Med., January 16, 2003; 348(3): 203 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Lenzi, M. Rosenblum, C. Verschraegen, A. P. Kudelka, J. J. Kavanagh, M. E. Hicks, E. A. Lang, M. A. Nash, L. B. Levy, M. E. Garcia, et al. Phase I Study of Intraperitoneal Recombinant Human Interleukin 12 in Patients with Mullerian Carcinoma, Gastrointestinal Primary Malignancies, and Mesothelioma Clin. Cancer Res., December 1, 2002; 8(12): 3686 - 3695. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Schutyser, S. Struyf, P. Proost, G. Opdenakker, G. Laureys, B. Verhasselt, L. Peperstraete, I. Van de Putte, A. Saccani, P. Allavena, et al. Identification of Biologically Active Chemokine Isoforms from Ascitic Fluid and Elevated Levels of CCL18/Pulmonary and Activation-regulated Chemokine in Ovarian Carcinoma J. Biol. Chem., June 28, 2002; 277(27): 24584 - 24593. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Y. Woo, C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S. C. Rubin, L. R. Kaiser, and C. H. June Regulatory CD4+CD25+ T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer Cancer Res., June 1, 2001; 61(12): 4766 - 4772. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsuoka, H. Tabata, and S. Matsushita Monocytes Are Differentially Activated Through HLA-DR, -DQ, and -DP Molecules Via Mitogen-Activated Protein Kinases J. Immunol., February 15, 2001; 166(4): 2202 - 2208. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Freedman, A. P. Kudelka, J. J. Kavanagh, C. Verschraegen, C. L. Edwards, M. Nash, L. Levy, E. N. Atkinson, H.-Z. Zhang, B. Melichar, et al. Clinical and Biological Effects of Intraperitoneal Injections of Recombinant Interferon-{{gamma}} and Recombinant Interleukin 2 with or without Tumor-infiltrating Lymphocytes in Patients with Ovarian or Peritoneal Carcinoma Clin. Cancer Res., June 1, 2000; 6(6): 2268 - 2278. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |